KOD - Kodiak Sciences CMO resigns following failed Phase 3 studies for lead drug
2023-08-17 18:21:38 ET
More on Kodiak Sciences
- Kodiak Sciences: Navigating Clinical Trials And A Competitive Landscape
- Kodiak cut to Neutral at UBS as lead asset dropped from trials
- Biggest stock movers today: Nikola, AMC Entertainment, POSCO Holdings and more
- Kodiak drops eye disease candidate after Phase 3 setback
- Kodiak gains as late-stage trial for eye disease candidate meets key goal
- Seeking Alpha’s Quant Rating on Kodiak Sciences
- Earnings data for Kodiak Sciences
For further details see:
Kodiak Sciences CMO resigns following failed Phase 3 studies for lead drug